Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome–Positive Acute Lymphoblast Leukemia: A Systematic Review

医学 达沙替尼 内科学 伊马替尼 尼罗替尼 肿瘤科 移植 费城染色体 造血干细胞移植 回顾性队列研究 甲磺酸伊马替尼 髓系白血病 染色体易位 基因 生物化学 化学
作者
Zabih Warraich,Pavan Tenneti,Theresa Thai,Anne Hubben,Hina Amin,Ali McBride,Sami Ullah Warraich,Abdul Hannan,Faiza Hassan Warraich,Navneet S. Majhail,Matt Kalaycio,Faiz Anwer
出处
期刊:Biology of Blood and Marrow Transplantation [Elsevier BV]
卷期号:26 (3): e55-e64 被引量:53
标识
DOI:10.1016/j.bbmt.2019.09.022
摘要

Abstract

Relapse after stem cell transplantation for Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) remains a significant challenge. In this systematic review, we compare survival outcomes of second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib with first-generation TKI imatinib when these agents are used after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Ph+ ALL. In addition, we review the literature on TKI use to prevent relapse in patients who proceed to allo-HSCT beyond first complete response (>CR1). We performed database searches (inception to January 2018) using PubMed, Cochrane Library, and Embase. After exclusions, 17 articles were included in this analysis. Imatinib was used post-transplant either prophylactically or preemptively in 12 studies, 7 prospective studies and 5 retrospective studies. Overall survival (OS) for most prospective studies at 1.5 to 3 and 5 years ranged between 62% to 92% and 74.5% to 86.7%. Disease-free survival at 1.5 to 5 years was 60.4% to 92%. Additionally, imatinib failed to show survival benefit in patients who were >CR1 at the time of allo-HSCT. The cumulative OS for most retrospective studies using imatinib at 1 to 2 and 3 to 5 years was 42% to 100% and 33% to 40% respectively. Event-free survival at 1 to 2 and 3 to 5 years was 33.3% to 67% and 20% to 31% respectively. Dasatinib was used as maintenance treatment in 3 retrospective studies (n = 34). The OS for patients with Ph+ ALL using dasatinib as maintenance regimen after allo-HSCT at 1.4 to 3 years was 87% to 100% and disease-free survival at 1.4 to 3 years was 89% to 100%. Ninety-three percent of patients with minimal residual disease (MRD) positive status after allo-HSCT became MRD negative. Three prospective studies used nilotinib. In 2 studies where investigators studied patients with advanced chronic myeloid leukemia and Ph+ ALL, the cumulative OS and event-free survival at 7.5 months to 2 years were 69% to 84% and 56% to 84%, respectively. In the third study (n = 5) in patients with Ph+ ALL, nilotinib use resulted in OS at 5 years of 60%. Our review showed that use of TKIs (all generations) after allo-HSCT for patients in CR1 improved OS when given as a prophylactic or preemptive regimen. Limited data suggest that second-generation TKIs (ie, dasatinib) have a better OS, especially in patients with MRD-positive status. Imatinib did not improve OS in patients who were >CR1 at the time of allo-HSCT; for this population, no data were available with newer generation TKIs. The evaluation of survival benefit with newer generation TKIs and their efficacy in patients in >CR1 needs further study in large randomized clinical trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
缓慢海亦完成签到,获得积分20
刚刚
刚刚
脑洞疼应助黄h采纳,获得10
刚刚
完美世界应助Du采纳,获得10
刚刚
ye关闭了ye文献求助
刚刚
1秒前
温暖发布了新的文献求助10
2秒前
友好凡霜完成签到,获得积分10
2秒前
万能图书馆应助罗某人采纳,获得10
2秒前
量子星尘发布了新的文献求助30
2秒前
风华完成签到,获得积分10
3秒前
3秒前
Phuong完成签到,获得积分10
3秒前
ok123完成签到 ,获得积分10
4秒前
苏小北完成签到 ,获得积分10
4秒前
4秒前
5秒前
5秒前
缓慢海亦发布了新的文献求助10
5秒前
6秒前
科研麻瓜完成签到,获得积分20
6秒前
7秒前
开心人达发布了新的文献求助10
8秒前
小雨完成签到,获得积分10
8秒前
燕燕于飞发布了新的文献求助30
8秒前
ayuelei发布了新的文献求助10
9秒前
完美世界应助灵76采纳,获得10
9秒前
碧蓝的青荷完成签到,获得积分20
11秒前
12秒前
完美世界应助飞飞采纳,获得10
13秒前
13秒前
14秒前
14秒前
利乐完成签到,获得积分10
15秒前
小雨发布了新的文献求助10
15秒前
yiyi037118发布了新的文献求助10
16秒前
清新的宛丝完成签到,获得积分10
16秒前
17秒前
柯一一应助燕燕于飞采纳,获得10
17秒前
orixero应助稀里糊涂图采纳,获得20
18秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969513
求助须知:如何正确求助?哪些是违规求助? 3514327
关于积分的说明 11173617
捐赠科研通 3249672
什么是DOI,文献DOI怎么找? 1794973
邀请新用户注册赠送积分活动 875537
科研通“疑难数据库(出版商)”最低求助积分说明 804836